Cagrilintide vs Mazdutide
Cagrilintide and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Cagrilintide
Dossier overview
Mazdutide
Dossier overview
What the evidence actually compares
Cagrilintide is a long-acting amylin analogue studied alone and with semaglutide. Mazdutide is a single GLP-1/glucagon dual agonist. Results from CagriSema, the cagrilintide-plus-semaglutide combination, are not cagrilintide monotherapy results.
A published phase 2 randomized dose-finding trial tested cagrilintide monotherapy against placebo and an active comparator in adults with overweight or obesity. REDEFINE 1 also contained a cagrilintide-alone arm, but its combination-arm primary finding cannot be assigned to that monotherapy arm. Cagrilintide phase 2, PMID 34798060 · REDEFINE 1, PMID 40544433
Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2
Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.
| Evidence question | Cagrilintide | Mazdutide |
|---|---|---|
| Mechanism | Cagrilintide is a long-acting amylin analogue studied alone and with semaglutide. Mazdutide is a single GLP-1/glucagon dual agonist. Results from CagriSema, the cagrilintide-plus-semaglutide combination, are not cagrilintide monotherapy results. | GLP-1/glucagon receptor dual agonist |
| Cited human weight evidence | Published monotherapy phase 2 randomized study | Published GLORY phase 3 studies in Chinese adults; separate US phase 2 study |
| US status in reviewed sources | No FDA approval verified | No FDA approval verified |
| China status in reviewed sources | No jurisdiction-specific conclusion from cited Cagrilintide sources | Innovent reports specified adult weight and diabetes approvals |
What cannot be inferred
Both substances have human randomized weight studies, but they work through different receptor systems and were tested in separate trials. No cited study directly compares cagrilintide monotherapy with mazdutide.
Cagrilintide monotherapy remained investigational in the reviewed sources; no FDA approval for it or mazdutide was verified. China-specific mazdutide approval is a separate sponsor-reported claim. The source for the Cagrilintide evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.
This comparison is educational research context, not medical advice or a treatment protocol.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.